Skip to main content

Massachusetts General Hospital to Use CERCARE Perfusion in Neuroradiology Research

CERCARE Perfusion to be used by Massachusetts General Hospital’s Athinoula A. Martinos Center for Biomedical Imaging (MGH Martinos Center) to assess lesion progression of adrenoleukodystrophy patients.

Aarhus, Denmark (May 26, 2021) – Cercare Medical proudly announces that Massachusetts General Hospital’s Athinoula A. Martinos Center for Biomedical Imaging (MGH Martinos Center) is now using CERCARE Perfusion in their research. CERCARE Perfusion incorporates capillary transit time heterogeneity information to produce high-quality maps showing oxygen extraction and metabolic biomarkers that were previously unavailable from CT and MRI imaging. The software integrates artificial intelligence (AI) and offers fully autonomous postprocessing. MGH Martinos will be using CERCARE Perfusion for research of adrenoleukodystrophy patients.

“We are honored that MGH Martinos Center will continue using CERCARE Perfusion in their studies. We are proud of our long-term collaboration and the important discoveries it brings. This furthers our understanding of blood flow and tissue oxygenation as central mechanisms in many disorders. Cercare Medical is pleased to contribute to the improvement of treatment options for patients with this critical condition,” said Kim Beuschau Mouridsen, founder and Chief Executive Officer of Cercare Medical.

“Researchers at Massachusetts General Hospital (MGH) are using Cercare Medical’s perfusion imaging software suite to quantitatively assess lesion progression of adrenoleukodystrophy patients in an ongoing clinical trial. Perfusion derived maps such as the Oxygen Extraction Fraction (OEF), Capillary Transit Time Heterogeneity (CTH), and Cerebral Metabolic Rate of Oxygen (CMRO2) provide subtle clues regarding the future potential for lesion progression that are not visibly appreciable on conventional MR such at T1 or T2 weighted imaging. Thus, by better stratifying patients by risk of progression, we envision that this work will enable more personalized and timely treatment options.”

CERCARE Perfusion is unique in the neuroimaging market in utilizing an innovative approach to perfusion imaging that makes it possible to offer perfusion biomarkers of oxygen extraction and metabolism. The program is used for research and pathology assessment in a range of neurological diseases including brain tumors, dementia and acute ischemic stroke. Researchers and clinicians can use the information obtained to better understand the patient’s microvascular flow and brain tissue oxygenation through highly informative and easy-to-read maps.

The solution is fully automated. Where traditionally the arterial input function (AIF) is manually selected, which can lead to different outputs and delays in image assessment, CERCARE Perfusion uses Artificial Intelligence technology to fully automate the process allowing for image standardization and workflow improvement in clinical and research settings.

The PDF version of the press release is available here.

On-Demand Webinar

Learn more about the role capillary function and integrity play in a range of neurological disorders and how our unique biomarkers can help you get deeper insights into brain tissue oxygenation.